<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142843">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797484</url>
  </required_header>
  <id_info>
    <org_study_id>UHZ-KARD-01-2013</org_study_id>
    <nct_id>NCT01797484</nct_id>
  </id_info>
  <brief_title>Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia</brief_title>
  <acronym>RIMINI-Pilot</acronym>
  <official_title>Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in
      acute myocardial ischemia.

      A pilot-trial by Venkatamaran et al. recently demonstrated, that the area of ischemic
      myocardium in patients with stable coronary artery disease can be reduced by
      Ranolazine-treatment2. This effect was shown by significantly reduced areas of atypical or
      dysfunctional myocardium in SPECT-examinations.

      The dimension of myocardial damage (i.e. area of ischemic myocardium) is directly related to
      the rate of complications (i.e. left-ventricular pump failure, malignant arrhythmia) and the
      grade of Rehabilitation to daily life (i.e. persistent reduced left-ventricular ejection
      fraction).

      In patients with stable angina pectoris, Ranolazine is used with beneficial results1.
      Ranolazine improves diastolic blood flow and therefore microcirculation in the myocardium by
      reducing diastolic tension (via inhibiting late Na+-Influx and consecutive Ca2+-Overload).

      Recently published data2 showed that treatment with Ranolazine significantly reduces the
      ischemic area in chronic damaged myocardium. This is due the effect of improved
      microcirculation in hibernating myocardium.

      Early administration of Ranolazine and improvement of microcirculation in patients with
      acute damaged myocardium (i.e. directly after acute ischemia) should lead to a recruitment
      and re-uptake of cardiac activity of hibernating myocardium.

      For the RIMINI-Trial patients are given Ranolazine on top of the guideline-based treatment
      to reduce the area of acute ischemic myocardium.

      Patients with unstable angina pectoris and proof of acute cardiac ischemia, proof of
      myocardial dyskinesia and angina pectoris in the patient history will receive unaltered
      guideline-based therapy for acute cardiac ischemia5,6. All necessary procedures will be
      performed to stabilize patients to a hemodynamically compensated state and patients are then
      transferred to receive cardiac catheterization (angiography and angioplasty if necessary).

      After patients are stabilized Ranolazine will be given additionally to guideline based
      medication.

      The measurement of the ischemic myocardial area will be done via three functional
      echocardiographies with speckle tracking technique10.

      A statistical evaluation of ischemic myocardial area before and after treatment with
      Ranolazine/Placebo will be done after conclusion of the RIMINI-Trial to show the effect of
      Ranolazine in acute myocardial ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in
      acute myocardial ischemia.

      A pilot-trial by Venkatamaran et al. recently demonstrated, that the area of ischemic
      myocardium in patients with stable coronary artery disease can be reduced by
      Ranolazine-treatment2. This effect was shown by significantly reduced areas of atypical or
      dysfunctional myocardium in SPECT-examinations.

      The dimension of myocardial damage (i.e. area of ischemic myocardium) is directly related
      to:

        1. Rate of complications (i.e. left-ventricular pump failure, malignant arrhythmia)

        2. Grade of Rehabilitation to daily life (i.e. persistent reduced left-ventricular
           ejection fraction)

      Early angioplasty and coronary medication are key factors for preventing complications and
      ensuring sufficient rehabilitation. This is done to reduce the ischemic area as best as
      possible.

      In patients with stable angina pectoris, Ranolazine is used with beneficial results1.
      Ranolazine improves diastolic blood flow and therefore microcirculation in the myocardium by
      reducing diastolic tension (via inhibiting late Na+-Influx and consecutive Ca2+-Overload).

      Recently published data2 showed that treatment with Ranolazine significantly reduces the
      ischemic area in chronic damaged myocardium. This is due the effect of improved
      microcirculation in hibernating myocardium.

      Early administration of Ranolazine and improvement of microcirculation in patients with
      acute damaged myocardium (i.e. directly after acute ischemia) should lead to a recruitment
      and re-uptake of cardiac activity of hibernating myocardium.

      For the RIMINI-Trial patients are given Ranolazine on top of the guideline-based treatment
      to reduce the area of acute ischemic myocardium.

      Patients with unstable angina pectoris and proof of acute cardiac ischemia (Serum levels of
      Troponin-T-hs &gt;14 pg/ml), proof of myocardial dyskinesia and angina pectoris &gt;/=CCS II
      (Canadian Cardiovascular Society Classification of Angina Pectoris) in the patient history
      will receive unaltered guideline-based therapy for acute cardiac ischemia5,6. All necessary
      procedures will be performed to stabilize patients to a hemodynamically compensated state
      (normalized levels of blood pressure, heart rate, absent malignant arrhythmia, dyspnoea and
      angina-like symptoms), and patients are then transferred to receive cardiac catheterization
      (angiography and angioplasty if necessary).

      After patients are stabilized (i.e. via angioplasty, medical treatment) Ranolazine will be
      given additionally to guideline-based medication (Beta-Blocker, ACE-Inhibitor or
      AT1-Inhibitor, ASS, Clopidogrel, Statins).

      The measurement of the ischemic myocardial area will be done via three functional
      echocardiographies with speckle tracking technique10 (speckle -tracking echocardiography,
      SPE):

        1. The first speckle tracking for screening and will be done directly with patients
           presenting in the emergency room.

        2. After stabilization and coronary angiography or -plasty and before the first dose of
           Ranolazine is given, the second speckle tracking will be done for baseline.

        3. After 42 days of Ranolazine-treatment the third and final speckle tracking
           echocardiography will be done.

      A statistical evaluation of ischemic myocardial area before and after treatment with
      Ranolazine/Placebo will be done after conclusion of the RIMINI-Trial to show the effect of
      Ranolazine in acute myocardial ischemia.

      For controlling and comparing the effect, the RIMINI-Trial will be single-blinded and
      compared to a group of patients not treated with Ranolazine. Participants will be randomized
      to the treatment-group or the no-treatment-group using a computer based
      randomization-method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area of ischemic myocardium/cm² (longitudinal strain, radial/circumferential strain)</measure>
    <time_frame>42 days after first dose of Ranolazine</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiac complications (i.e. ventricular tachycardia, re-infarction, rehospitalisation for revascularization)</measure>
    <time_frame>42 days after first dose of Ranolazine</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of cardiac markers (NT-pro-BNP, Troponin, CK, Copeptin)</measure>
    <time_frame>Before and 42 days after first dose of Ranolazine</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No additional medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional medication - control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Improvement of myocardial microcirculation</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proof of acute cardiac ischemia by elevated serum Troponin T-hs levels &gt; 14  pg/nl

          -  Proof of myocardial dyskinesia with functional echocardiography (&quot;speckle tracking&quot;)

          -  Stable angina pectoris &gt;/= CCS II in patient history

          -  Stabilized (i.e. normalized vital parameters) patients after coronary angioplasty or
             angiography

          -  Coronary angioplasty or angiography not older than 24 hours

          -  Written informed consent

          -  Established standard therapy for coronary artery disease (i.e. Beta-Blocker,
             ACE-Inhibitor or AT1-Inhibitor, ASS, Clopidogrel, Statins)

        Exclusion Criteria:

          -  Patients younger than 18 years of age

          -  Acute cardio-pulmonary decompensation

          -  Middle and high grade liver insufficiency (Child-Pugh Score B and C)

          -  High grade renal insufficiency (Creatinine-Clearance &lt; 30 ml/min)

          -  Concomitant treatment with potent inhibitors of CYP3A4

          -  Concomitant administration of class Ia (e.g. quinidine) or class III (e.g.
             dofetilide, sotalol) antiarrhythmics, except for amiodarone

          -  Concomitant administration of &gt; 20 mg simvastatin/day

          -  Patients with heart failure classification NYHA III and NYHA IV

          -  Homeless patients and drug-addicted patients

          -  Pregnant and/or breast-feeding women

          -  Treatment with Ranolazine prior to enrolment in RIMINI-Trial

          -  Allergy against Ranolazine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Blankenberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of University Heart Center Hamburg Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tjark F Schwemer, MD</last_name>
    <phone>+49407410</phone>
    <phone_ext>56800</phone_ext>
    <email>t.schwemer@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Britta Goldmann, MD</last_name>
    <phone>+49407410</phone>
    <phone_ext>56800</phone_ext>
    <email>goldmann@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Heart Center Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tjark F Schwemer, MD</last_name>
      <phone>+49407410</phone>
      <phone_ext>56800</phone_ext>
      <email>t.schwemer@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Britta Goldmann, MD</last_name>
      <phone>+49407410</phone>
      <phone_ext>56800</phone_ext>
      <email>goldmann@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tjark F Schwemer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Britta Goldmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Peitsmeyer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Friedrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uhz.de</url>
    <description>University Heart Center Hamburg Eppendorf</description>
  </link>
  <reference>
    <citation>Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83.</citation>
    <PMID>17456819</PMID>
  </reference>
  <reference>
    <citation>Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009 Nov;2(11):1301-9. doi: 10.1016/j.jcmg.2009.09.006.</citation>
    <PMID>19909934</PMID>
  </reference>
  <reference>
    <citation>El-Kadri M, Sharaf-Dabbagh H, Ramsdale D. Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTE-ACS). Cardiovasc Ther. 2012 Feb;30(1):e16-22. doi: 10.1111/j.1755-5922.2010.00225.x. Epub 2010 Sep 15. Review.</citation>
    <PMID>20840192</PMID>
  </reference>
  <reference>
    <citation>Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. Epub 2008 Nov 12. No abstract available.</citation>
    <PMID>19004841</PMID>
  </reference>
  <reference>
    <citation>Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. Epub 2007 Jun 14.</citation>
    <PMID>17569677</PMID>
  </reference>
  <reference>
    <citation>Andersen GØ, Knudsen EC, Aukrust P, Yndestad A, Oie E, Müller C, Seljeflot I, Ueland T. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart. 2011 Mar;97(6):460-5. doi: 10.1136/hrt.2010.206714. Epub 2011 Jan 26.</citation>
    <PMID>21270073</PMID>
  </reference>
  <reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </reference>
  <reference>
    <citation>Miller TD, Gibbons RJ. Measuring myocardium at risk in acute myocardial infarction--a continuing challenge. J Nucl Cardiol. 2010 Oct;17(5):778-80. doi: 10.1007/s12350-010-9278-3.</citation>
    <PMID>20717762</PMID>
  </reference>
  <reference>
    <citation>Geyer H, Caracciolo G, Abe H, Wilansky S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Sengupta PP. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010 Apr;23(4):351-69; quiz 453-5. doi: 10.1016/j.echo.2010.02.015. Erratum in: J Am Soc Echocardiogr. 2010 Jul;23(7):734.</citation>
    <PMID>20362924</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Tjark Frederik Schwemer</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ischemia</keyword>
  <keyword>myocardium</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>speckle tracking echocardiography</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
